Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INT230-6 · INT230

Small molecule · developed by Intensity Therapeutics

Phase 3 Most advanced trial
INTS Developer
1 Registered trials

What is INT230-6?

INT230-6 is a fixed-dose combination of cisplatin, vinblastine and SHAO. It is being studied in soft tissue sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INT230
Drug type
Small molecule
Therapy area
Oncology
Developer
Intensity Therapeutics, Inc. (INTS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06263231 Phase 3 Sarcoma,Soft Tissue Recruiting INTS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sarcoma,Soft Tissue

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INTS page.

Follow INTS, the company behind INT230-6

See INTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INTS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.